



FOXO4-DRI

CAS NUMBER
2460055-10-9MOLECULAR FORMULA
C228H388N86O64MOLECULAR WEIGHT
5358 g/molSALT FORM
Trifluoroacetate (TFA)SEQUENCE
All-D retro-inverso FOXO4 peptide (D-Arg-rich cell-penetrating segment fused to reversed FOXO4 p53-binding domain)LOT NUMBER
FXO-2609ADATE OF ANALYSIS
September 22, 2026RETEST DATE
September 21, 2028ANALYTICAL LABORATORY
Third-party HPLC/MS

ANALYTICAL RESULTS

TEST	METHOD	SPECIFICATION	RESULT
Appearance	Visual	White to off-white lyophilized powder	Conforms
Identity (molecular mass)	ESI-MS	5358 g/mol +/- 1.0 Da	5358.1 Da
Purity	RP-HPLC, UV 214 nm	NLT 98.0%	98.80%
Single largest impurity	RP-HPLC, UV 214 nm	NMT 1.0%	0.26%
Water content	Karl Fischer titration	NMT 8.0%	4.6%
Trifluoroacetate content	Ion chromatography	NMT 10.0%	7.6%
Peptide content	Nitrogen determination	NLT 80.0%	86%
Residual solvents	GC headspace, ICH Q3C	Meets ICH limits	Conforms
Bacterial endotoxins	LAL, USP <85>	< 1.0 EU/mg	Conforms

CONFORMS — lot FXO-2609A meets all specifications listed above.

CHROMATOGRAPHIC CONDITIONS

Column: C18 reversed phase, 4.6 × 250 mm, 5 µm, 100 Å
Mobile phase A: 0.1% TFA in water · B: 0.1% TFA in acetonitrile
Gradient: 5-65% B over 30 min · Flow: 1.0 mL/min · 25 °C
Detection: UV 214 nm · Injection volume: 20 µL
Mass spectrometry: ESI, positive ion mode

STORAGE & HANDLING

Lyophilized: -20°C, protected from light and moisture.
2-8°C acceptable short term. Equilibrate to room temperature before opening.

RELEASED BY
Quality Control, Ascendtials LLCDATE OF ISSUE
September 22, 2026**FOR LABORATORY RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE.**

This certificate applies only to the lot identified above. Not for use in food, drugs, medical devices, or cosmetics.

Ascendtials LLC · COA-FXO-2609A · ascendtials.shop